Synlogic Appoints New Chief Medical and Business Officers
Ticker: SYBX · Form: 8-K · Filed: Jan 14, 2025 · CIK: 1527599
| Field | Detail |
|---|---|
| Company | Synlogic, Inc. (SYBX) |
| Form Type | 8-K |
| Filed Date | Jan 14, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel
TL;DR
Synlogic beefs up exec team with CMO & CBO hires.
AI Summary
On January 10, 2025, Synlogic, Inc. announced the appointment of Dr. Antoine Yver as Chief Medical Officer and Dr. Michael J. Ybarra as Chief Business Officer. Dr. Yver previously served as Chief Medical Officer at Kadmon Pharmaceuticals, and Dr. Ybarra was previously Chief Business Officer at Cerevel Therapeutics.
Why It Matters
The appointment of experienced executives in key medical and business roles suggests Synlogic is strengthening its leadership team to advance its drug development pipeline and commercial strategy.
Risk Assessment
Risk Level: medium — The appointment of new senior executives can introduce uncertainty regarding strategic direction and integration, though their experience may mitigate risks.
Key Players & Entities
- Synlogic, Inc. (company) — Registrant
- Dr. Antoine Yver (person) — Appointed Chief Medical Officer
- Dr. Michael J. Ybarra (person) — Appointed Chief Business Officer
- Kadmon Pharmaceuticals (company) — Dr. Yver's former employer
- Cerevel Therapeutics (company) — Dr. Ybarra's former employer
FAQ
What are the effective dates for the appointments of the new officers?
The filing does not specify an effective date for the appointments, but the report is dated January 10, 2025.
What were the previous roles of Dr. Antoine Yver and Dr. Michael J. Ybarra?
Dr. Antoine Yver was previously Chief Medical Officer at Kadmon Pharmaceuticals, and Dr. Michael J. Ybarra was previously Chief Business Officer at Cerevel Therapeutics.
What is Synlogic, Inc.'s primary business?
Synlogic, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
Where is Synlogic, Inc. headquartered?
Synlogic, Inc.'s principal executive offices are located at PO Box 30, Winchester, Massachusetts, 01890.
Has Synlogic, Inc. had a former company name?
Yes, Synlogic, Inc. was formerly known as Mirna Therapeutics, Inc., with a name change date of August 9, 2011.
Filing Stats: 446 words · 2 min read · ~1 pages · Grade level 12.7 · Accepted 2025-01-14 17:00:08
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share SYBX The NASDAQ Capital M
Filing Documents
- sybx-20250110.htm (8-K) — 40KB
- 0000950170-25-005425.txt ( ) — 195KB
- sybx-20250110.xsd (EX-101.SCH) — 55KB
- sybx-20250110_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: January 14, 2025 Synlogic, Inc. By: /s/ Mary Beth Dooley Name: Title: Mary Beth Dooley Principal Executive Officer and Principal Financial Officer